Reimagining Medicine for Patients With Breast Cancer
Reimagining Medicine for Patients With Breast Cancer
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
MOA is based on in vitro/in vivo data. Clinical benefit is unknown.
aBC = advanced breast cancer; DNA = deoxyribonucleic acid; HER2- = human epidermal growth factor receptor 2 negative; HER2+ = human epidermal growth factor receptor 2 positive; HR+ = hormone receptor positive; PI3K = phosphoinositol 3 kinase; TNBC = triple-negative breast cancer.


Explore Clinical Trials
Explore Clinical Trials


Adjuvant HER2+
Trastuzamab + Pertuzumab + Alpelisib as Maintenance Therapy in PIK3CA Mutated HER2+ Advanced Breast Cancer


Advanced TNBC
Alpelisib Plus Nab-pacitaxel in Patients With Advanced Triple-Negative Breast Cancer With PIK3CA Mutation or PTEN Loss Without PIK3CA Mutation


HR+/HER2- ABC
Study of the Safety and Efficacy of Dapagliflozin + Metformin XR vs Metformin XR During Treatment With Alpelisib and Fulvestrant in Patients With HR+, HER2-, PIK3CA mutation-positive Advanced Breast Cancer


HR+/HER2- ABC
Alpelesib + Fulvestrant in Patients with HR+, HER2- Advanced Breast Cancer After Treatment with a CDK4/6 Inhibitor and an Aromatase Inhibitor


HGSOC
Alpelisib + Olaparib in Platinum-Resistant or Refractory, Germline BRCA Mutation Negative High-grade Serous Ovarian Cancer
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
Explore Compounds
Explore Compounds


PI3K small-molecule inhibitor


PD-1–targeting monoclonal antibody